136 related articles for article (PubMed ID: 37775370)
1. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Brambilla M; Beninato T; Piemontese A; Mazzeo L; Pircher CC; Manglaviti S; Ambrosini P; Signorelli D; Lorenzini D; Prelaj A; Ferrara R; Proto C; Lo Russo G; Pizzutilo EG; Ganzinelli M; Grande I; Capone I; Di Mauro RM; Conca E; Dumitrascu AD; Zanella C; Leporati R; Rota S; Garassino MC; Marchetti P; de Braud FM; Occhipinti M
Clin Lung Cancer; 2023 Nov; 24(7):631-640.e2. PubMed ID: 37775370
[TBL] [Abstract][Full Text] [Related]
2. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
3. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
5. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J
J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
7. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M; Kuon J; Lüders H; Misch D; Kauffmann-Guerrero D; Hilbrandt M; Kazdal D; Falkenstern-Ge RF; Hackanson B; Dintner S; Faehling M; Kirchner M; Volckmar AL; Kopp HG; Allgäuer M; Grohé C; Tufman A; Reck M; Frost N; Stenzinger A; Thomas M; Christopoulos P
Eur J Cancer; 2024 Mar; 199():113556. PubMed ID: 38271745
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y
Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O
Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
12. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
[TBL] [Abstract][Full Text] [Related]
13. Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.
Janzic U; Shalata W; Szymczak K; Dziadziuszko R; Jakopovic M; Mountzios G; Płużański A; Araujo A; Charpidou A; Agbarya A
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629023
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first-line therapy in adenocarcinoma patients.
Wang M; Li J; Xu S; Li Y; Li J; Yu J; Tang X; Zhu H
Cancer Med; 2023 Mar; 12(5):5352-5363. PubMed ID: 36271595
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Guisier F; Dubos-Arvis C; Viñas F; Doubre H; Ricordel C; Ropert S; Janicot H; Bernardi M; Fournel P; Lamy R; Pérol M; Dauba J; Gonzales G; Falchero L; Decroisette C; Assouline P; Chouaid C; Bylicki O
J Thorac Oncol; 2020 Apr; 15(4):628-636. PubMed ID: 31945494
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
17. First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis.
Mao Z; Jiang P; Zhang Y; Li Y; Jia X; Wang Q; Jiao M; Jiang L; Shen Y; Guo H
Cancer Med; 2021 Dec; 10(24):9139-9155. PubMed ID: 34747149
[TBL] [Abstract][Full Text] [Related]
18. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
[TBL] [Abstract][Full Text] [Related]
19. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Goring S; Varol N; Waser N; Popoff E; Lozano-Ortega G; Lee A; Yuan Y; Eccles L; Tran P; Penrod JR
Lung Cancer; 2022 Aug; 170():122-132. PubMed ID: 35767923
[TBL] [Abstract][Full Text] [Related]
20. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.
Liu Y; Zhang Z; Rinsurongkawong W; Gay CM; Le X; Ning MS; Lewis J; Rinsurongkawong V; Lee JJ; Roth J; Swisher S; Gandhi S; Lee PP; Gibbons DL; Vaporciyan AA; Heymach JV; Zhang J; Lin SH
JAMA Netw Open; 2022 Jun; 5(6):e2215589. PubMed ID: 35666500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
